TableĀ 2

Levers impacting trial site selection for early and late trials

LeverResponse meanUpper 95% CLLower 95% CL
Early phaseLate phaseEarly phaseLate phaseEarly phaseLate phase
Investigator factors30.229.131.530.428.927.8
Hospital/unit factors28.428.329.729.727.026.9
Environmental factors25.523.526.624.724.322.4
Cost factors16.019.017.220.414.717.7
  • Respondents (N=341) were asked to divide 100 points across the above four levers impacting their trial site selection for early phase studies: Pharma, Biotech, CROs and CTUs answered for phase II (2) studies. Medical device and all others answered for phase III (3) studies. Then respondents were asked to do the same as above for later phase studies: Pharma, Biotech, CROs and CTUs answered for phase III (3) studies. Medical device and all others answered for phase IV (4) studies. There was evidence of a statistically significant difference in the level of importance of the four factors (p<0.0001). The pattern of response (not shown here) appeared to be consistent across survey respondent groupings (ie, CTU vs CRO vs industry).

  • CL, confidence limit; CROs, clinical research organisations; CTUs, clinical trial units.